<p>在比利時，<strong>百威英博</strong>（EBR:ABI）的市盈率為 16.5 倍，似乎並不值得一提，因為該國的中位市盈率大約為 16 倍。不過，簡單忽視市盈率而不加解釋並不明智，因為投資者可能會忽略一個獨特的機會或犯下一個代價高昂的錯誤。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>最近一段時間對百威英博來説是有利的，因為其收益增長速度超過了大多數其他公司。一個可能性是，市盈率適中是因為投資者認為這種強勁的收益表現可能即將減弱。如果你喜歡這家公司，你會希望這種情況不會發生，這樣你就可以在它還不太受歡迎時買入一些股票。</p>
<p>查看我們對百威英博的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/745257-pe-multiple-vs-industry-1-dark-2/1757318273399?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/745257-pe-multiple-vs-industry-1-dark-2/1757318273399"/></p>
<p>ENXTBR:ABI 市盈率與行業比較 2025 年 9 月 8 日</p>
<p>如果你想了解分析師對未來的預測，可以查看我們關於百威英博的 <strong>免費</strong> 報告。</p>
<h2>增長是否與市盈率匹配？</h2>
<p>有一個內在的假設，即像百威英博這樣的公司，其市盈率應該與市場相匹配，才被認為是合理的。</p>
<p>首先回顧一下，我們看到該公司去年的每股收益增長了令人印象深刻的 21%。最近三年期間，每股收益整體增長了 88%，得益於其短期表現。因此，我們可以確認該公司在這段時間內成功地實現了收益增長。</p>
<p>展望未來，分析師預計接下來的三年每年將實現 13% 的增長。同時，市場的其他部分預計每年將擴展 11%，這並沒有實質性差異。</p>
<p>根據這些信息，我們可以看到為什麼百威英博的市盈率與市場相對接近。顯然，股東們願意在公司保持低調的同時繼續持有股票。</p>
<h2>關鍵要點</h2>
<p>僅僅使用市盈率來判斷是否應該出售你的股票並不明智，然而它可以作為公司未來前景的實用指南。</p>
<p>我們已經確定，百威英博的適中市盈率是基於其預測增長與更廣泛市場一致的預期。在這一階段，投資者認為收益改善或惡化的潛力不足以證明高或低市盈率的合理性。在這種情況下，很難看到股價在短期內有強勁的波動。</p>
<p>始終需要考慮投資風險的潛在威脅。我們已經發現了 <strong>百威英博的 1 個警告信號</strong>，理解這一點應該成為你投資過程的一部分。</p>
<p>當然，<strong>你也可能找到比百威英博更好的股票</strong>。因此，你可能希望查看這份 <strong>免費</strong> 的其他公司集合，這些公司具有合理的市盈率並且收益增長強勁。</p>

百威英博

<p>百威英博（Anheuser-Busch InBev SA/NV，EBR:ABI）的市盈率為 16.5 倍，略高於比利時的中位數 16 倍。儘管去年強勁的盈利增長達 21%，並且在三年內上漲了 88%，投資者可能對未來的表現持謹慎態度。分析師預測未來三年每股收益（EPS）將增長 13%，與市場預期一致。目前的市盈率反映了這一前景，暗示價格大幅波動的潛力有限。投資者在考慮其他投資機會時，應注意風險，包括一個已識別的警示信號</p>

<p>There wouldn't be many who think <strong>Anheuser-Busch InBev SA/NV's</strong> (EBR:ABI) price-to-earnings (or &#34;P/E&#34;) ratio of 16.5x is worth a mention when the median P/E in Belgium is similar at about 16x. Although, it's not wise to simply ignore the P/E without explanation as investors may be disregarding a distinct opportunity or a costly mistake.</p>
<div class="lb-trans"><p>在比利時，<strong>百威英博</strong>（EBR:ABI）的市盈率為 16.5 倍，似乎並不值得一提，因為該國的中位市盈率大約為 16 倍。不過，簡單忽視市盈率而不加解釋並不明智，因為投資者可能會忽略一個獨特的機會或犯下一個代價高昂的錯誤。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>Recent times have been advantageous for Anheuser-Busch InBev as its earnings have been rising faster than most other companies. One possibility is that the P/E is moderate because investors think this strong earnings performance might be about to tail off. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.</p>
<div class="lb-trans"><p>最近一段時間對百威英博來説是有利的，因為其收益增長速度超過了大多數其他公司。一個可能性是，市盈率適中是因為投資者認為這種強勁的收益表現可能即將減弱。如果你喜歡這家公司，你會希望這種情況不會發生，這樣你就可以在它還不太受歡迎時買入一些股票。</p>
</div><p>View our latest analysis for Anheuser-Busch InBev</p>
<div class="lb-trans"><p>查看我們對百威英博的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/745257-pe-multiple-vs-industry-1-dark-2/1757318273399" alt="" original-src="https://images.simplywall.st/asset/chart/745257-pe-multiple-vs-industry-1-dark-2/1757318273399"/></p>
<p>ENXTBR:ABI Price to Earnings Ratio vs Industry September 8th 2025</p>
<div class="lb-trans"><p>ENXTBR:ABI 市盈率與行業比較 2025 年 9 月 8 日</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Anheuser-Busch InBev.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們關於百威英博的 <strong>免費</strong> 報告。</p>
</div><h2>Does Growth Match The P/E?</h2>
<div class="lb-trans"><h2>增長是否與市盈率匹配？</h2>
</div><p>There's an inherent assumption that a company should be matching the market for P/E ratios like Anheuser-Busch InBev's to be considered reasonable.</p>
<div class="lb-trans"><p>有一個內在的假設，即像百威英博這樣的公司，其市盈率應該與市場相匹配，才被認為是合理的。</p>
</div><p>Taking a look back first, we see that the company grew earnings per share by an impressive 21% last year. The latest three year period has also seen an excellent 88% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.</p>
<div class="lb-trans"><p>首先回顧一下，我們看到該公司去年的每股收益增長了令人印象深刻的 21%。最近三年期間，每股收益整體增長了 88%，得益於其短期表現。因此，我們可以確認該公司在這段時間內成功地實現了收益增長。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 13% per year as estimated by the analysts watching the company. Meanwhile, the rest of the market is forecast to expand by 11% per year, which is not materially different.</p>
<div class="lb-trans"><p>展望未來，分析師預計接下來的三年每年將實現 13% 的增長。同時，市場的其他部分預計每年將擴展 11%，這並沒有實質性差異。</p>
</div><p>With this information, we can see why Anheuser-Busch InBev is trading at a fairly similar P/E to the market. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.</p>
<div class="lb-trans"><p>根據這些信息，我們可以看到為什麼百威英博的市盈率與市場相對接近。顯然，股東們願意在公司保持低調的同時繼續持有股票。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><p>Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>僅僅使用市盈率來判斷是否應該出售你的股票並不明智，然而它可以作為公司未來前景的實用指南。</p>
</div><p>We've established that Anheuser-Busch InBev maintains its moderate P/E off the back of its forecast growth being in line with the wider market, as expected. At this stage investors feel the potential for an improvement or deterioration in earnings isn't great enough to justify a high or low P/E ratio. It's hard to see the share price moving strongly in either direction in the near future under these circumstances.</p>
<div class="lb-trans"><p>我們已經確定，百威英博的適中市盈率是基於其預測增長與更廣泛市場一致的預期。在這一階段，投資者認為收益改善或惡化的潛力不足以證明高或低市盈率的合理性。在這種情況下，很難看到股價在短期內有強勁的波動。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>1 warning sign with Anheuser-Busch InBev</strong>, and understanding should be part of your investment process.</p>
<div class="lb-trans"><p>始終需要考慮投資風險的潛在威脅。我們已經發現了 <strong>百威英博的 1 個警告信號</strong>，理解這一點應該成為你投資過程的一部分。</p>
</div><p>Of course, <strong>you might also be able to find a better stock than Anheuser-Busch InBev</strong>. So you may wish to see this <strong>free</strong> collection of other companies that have reasonable P/E ratios and have grown earnings strongly.</p>
<div class="lb-trans"><p>當然，<strong>你也可能找到比百威英博更好的股票</strong>。因此，你可能希望查看這份 <strong>免費</strong> 的其他公司集合，這些公司具有合理的市盈率並且收益增長強勁。</p>
</div>

對百威英博 SA/NV（EBR:ABI）盈利感興趣的投資者